Study of bilateral elbow joint osteoarthritis treatment using conditioned medium from allogeneic adipose tissue-derived MSCs in Labrador retrievers

Hunakova et al., 2020
Full Study Link

Elita Summary

Osteoarthritis (OA) is one of the most common and challenging conditions seen in practice, and stem cell therapies are becoming an increasingly important option for management. New research suggests that the future of these treatments may extend beyond live cell injections to include cell-free approaches. This preliminary study investigated the use of a conditioned medium (CM), derived from allogeneic adipose-derived mesenchymal stem cells (AD-MSCs)—administered to dogs with bilateral elbow OA. The CM contains the paracrine and trophic factors secreted by MSCs, which are thought to be the primary drivers of therapeutic benefit. The findings support the potential of this cell-free method to reduce OA pain and improve joint function, offering a promising new avenue for treatment.

Study Design at a Glance
  • Sample: Six Labrador retriever dogs with a non-specific diagnosis of bilateral elbow OA were included in the study.
  • Methods:
    • Conditioned Medium: The conditioned medium was prepared from AD-MSCs sourced from a single, healthy, young donor dog.
    • Treatment: The six dogs received a double intra-articular injection of the conditioned medium into both elbow joints on Day 0 and Day 14.
  • Outcomes: The clinical effect was assessed on Day 0, Day 14, and Day 42.
    • Biomarker Analysis: Synovial fluid was collected and analyzed for changes in key inflammatory and anti-inflammatory biomolecules (e.g., MMP-3, TIMP-1, IL-6, TNF-α).
    • Functional Assessment: Kinematic analysis was used to objectively measure the Range of Motion (ROM) of the elbow joints before and after treatment.
Key Findings
  • Positive Effect on Inflammatory Biomarkers: The concentration of pro-inflammatory mediators MMP-3, IL-6, and TNF-α in the synovial fluid significantly decreased after the treatment. Concurrently, the anti-inflammatory marker TIMP-1 showed a significant increase.
  • Improved Range of Motion: The study found a significant improvement in the dogs' elbow joint ROM between Day 0 and Day 42, indicating enhanced functional ability.
  • Safety and Efficacy: The treatment was well-tolerated, with no severe adverse effects observed during the study period.

Why This Matters Clinically

  • Paracrine effect validated: The benefits of stem cells appear to come largely from the bioactive factors they secrete, not the cells themselves.
  • Cell-free options are emerging: Therapies like conditioned medium could provide a safer, more standardised alternative to live cell injections.
  • Less invasive, clinically relevant: These approaches may reduce concerns about immune compatibility or tumour risk while still improving pain and function.
  • Cell quality is critical: The effectiveness of any stem-cell-derived therapy depends on the quality of the starting cells—underscoring the value of banking while patients are young and healthy.

Implications for Elita

This study provides compelling evidence that the therapeutic power of mesenchymal stem cells lies in the potent factors they secrete. As Australia's only autologous stem cell bank for pets, this research directly supports our core belief: that collecting and banking a pet's cells when they are young and healthy is crucial. By cryopreserving a patient’s cells at their most vigorous state, we are not only saving the cells themselves but also ensuring the long-term availability of a highly potent source for producing future therapies, including cell-free applications like conditioned medium. We're committed to remaining at the forefront of this research to ensure the long-term value of what we're preserving for our clients.

‍